can semaglutide weaken immune system and Probiotics: A Science-Back Guide on How They Interact Semaglutide is a GLP-1 Receptor

Understanding NSAID interactions, individual risk factors, and provider oversight helps ensure safe concurrent use during weight management treatment

Semaglutide and tirzepatide for visceral fat and the thin-fat phenotype

N-terminal RIA

The pooled fixed-effect MantelHaenszel odds ratio was 0.99 (95% confidence interval 0.67 to 1.45

Obesity is increasingly considered an independent risk factor for pancreatic cancer, with excess adiposity driving neoplastic transformation through chronic inflammation, insulin resistance, hyperinsulinemia, and activation of oncogenic pathways

Conclusions Patients with T2D starting tirzepatide had greater HbA1c and weight reductions at 12 months post-initiation than those on injectable semaglutide, regardless of previous GLP-1 RA use, consistent with previous clinical trial results.